S Giordanengo1, M A Garella2, F Marchetto1, F Bourhaleb3, M Ciocca4, A Mirandola4, V Monaco3, M A Hosseini3, C Peroni3, R Sacchi3, R Cirio3, M Donetti2. 1. Istituto Nazionale di Fisica Nucleare, Section of Torino, Torino 10125, Italy. 2. Istituto Nazionale di Fisica Nucleare, Section of Torino, Torino 10125, Italy and Centro Nazionale Adroterapia Oncologica, Pavia 27100, Italy. 3. Istituto Nazionale di Fisica Nucleare, Section of Torino, Torino 10125, Italy and Physics Department, University of Torino, Torino 10125, Italy. 4. Centro Nazionale Adroterapia Oncologica, Pavia 27100, Italy.
Abstract
PURPOSE: This paper describes the system for the dose delivery currently used at the Centro Nazionale di Adroterapia Oncologica (CNAO) for ion beam modulated scanning radiotherapy. METHODS: CNAO Foundation, Istituto Nazionale di Fisica Nucleare and University of Torino have designed, built, and commissioned a dose delivery system (DDS) to monitor and guide ion beams accelerated by a dedicated synchrotron and to distribute the dose with a full 3D scanning technique. Protons and carbon ions are provided for a wide range of energies in order to cover a sizable span of treatment depths. The target volume, segmented in several layers orthogonally to the beam direction, is irradiated by thousands of pencil beams which must be steered and held to the prescribed positions until the prescribed number of particles has been delivered. For the CNAO beam lines, these operations are performed by the DDS. The main components of this system are two independent beam monitoring detectors, called BOX1 and BOX2, interfaced with two control systems performing the tasks of real-time fast and slow control, and connected to the scanning magnets and the beam chopper. As a reaction to any condition leading to a potential hazard, a DDS interlock signal is sent to the patient interlock system which immediately stops the irradiation. The essential tasks and operations performed by the DDS are described following the data flow from the treatment planning system through the end of the treatment delivery. RESULTS: The ability of the DDS to guarantee a safe and accurate treatment was validated during the commissioning phase by means of checks of the charge collection efficiency, gain uniformity of the chambers, and 2D dose distribution homogeneity and stability. A high level of reliability and robustness has been proven by three years of system activity needing rarely more than regular maintenance and working with 100% uptime. Four identical and independent DDS devices have been tested showing comparable performances and are presently in use on the CNAO beam lines for clinical activity. CONCLUSIONS: The dose delivery system described in this paper is one among the few worldwide existing systems to operate ion beam for modulated scanning radiotherapy. At the time of writing, it has been used to treat more than 350 patients and it has proven to guide and control the therapeutic pencil beams reaching performances well above clinical requirements. In particular, in terms of dose accuracy and stability, daily quality assurance measurements have shown dose deviations always lower than the acceptance threshold of 5% and 2.5%, respectively.
PURPOSE: This paper describes the system for the dose delivery currently used at the Centro Nazionale di Adroterapia Oncologica (CNAO) for ion beam modulated scanning radiotherapy. METHODS: CNAO Foundation, Istituto Nazionale di Fisica Nucleare and University of Torino have designed, built, and commissioned a dose delivery system (DDS) to monitor and guide ion beams accelerated by a dedicated synchrotron and to distribute the dose with a full 3D scanning technique. Protons and carbon ions are provided for a wide range of energies in order to cover a sizable span of treatment depths. The target volume, segmented in several layers orthogonally to the beam direction, is irradiated by thousands of pencil beams which must be steered and held to the prescribed positions until the prescribed number of particles has been delivered. For the CNAO beam lines, these operations are performed by the DDS. The main components of this system are two independent beam monitoring detectors, called BOX1 and BOX2, interfaced with two control systems performing the tasks of real-time fast and slow control, and connected to the scanning magnets and the beam chopper. As a reaction to any condition leading to a potential hazard, a DDS interlock signal is sent to the patient interlock system which immediately stops the irradiation. The essential tasks and operations performed by the DDS are described following the data flow from the treatment planning system through the end of the treatment delivery. RESULTS: The ability of the DDS to guarantee a safe and accurate treatment was validated during the commissioning phase by means of checks of the charge collection efficiency, gain uniformity of the chambers, and 2D dose distribution homogeneity and stability. A high level of reliability and robustness has been proven by three years of system activity needing rarely more than regular maintenance and working with 100% uptime. Four identical and independent DDS devices have been tested showing comparable performances and are presently in use on the CNAO beam lines for clinical activity. CONCLUSIONS: The dose delivery system described in this paper is one among the few worldwide existing systems to operate ion beam for modulated scanning radiotherapy. At the time of writing, it has been used to treat more than 350 patients and it has proven to guide and control the therapeutic pencil beams reaching performances well above clinical requirements. In particular, in terms of dose accuracy and stability, daily quality assurance measurements have shown dose deviations always lower than the acceptance threshold of 5% and 2.5%, respectively.
Authors: Amelia Barcellini; Viviana Vitolo; Lorenzo Cobianchi; Andrea Peloso; Alessandro Vanoli; Alfredo Mirandola; Angelica Facoetti; Maria Rosaria Fiore; Alberto Iannalfi; Barbara Vischioni; Francesco Cuccia; Sara Ronchi; Maria Bonora; Giulia Riva; Rachele Petrucci; Emma D'Ippolito; Francesca Dal Mas; Lorenzo Preda; Francesca Valvo Journal: In Vivo Date: 2020 May-Jun Impact factor: 2.155
Authors: Maria Giuseppina Bisogni; Andrea Attili; Giuseppe Battistoni; Nicola Belcari; Niccolo' Camarlinghi; Piergiorgio Cerello; Silvia Coli; Alberto Del Guerra; Alfredo Ferrari; Veronica Ferrero; Elisa Fiorina; Giuseppe Giraudo; Eleftheria Kostara; Matteo Morrocchi; Francesco Pennazio; Cristiana Peroni; Maria Antonietta Piliero; Giovanni Pirrone; Angelo Rivetti; Manuel D Rolo; Valeria Rosso; Paola Sala; Giancarlo Sportelli; Richard Wheadon Journal: J Med Imaging (Bellingham) Date: 2016-12-02
Authors: Arnold Pompos; Robert L Foote; Albert C Koong; Quynh Thu Le; Radhe Mohan; Harald Paganetti; Hak Choy Journal: Front Oncol Date: 2022-06-14 Impact factor: 5.738
Authors: Michelle Lis; Wayne Newhauser; Marco Donetti; Moritz Wolf; Timo Steinsberger; Athena Paz; Christian Graeff Journal: Front Oncol Date: 2021-09-08 Impact factor: 6.244
Authors: Martina Moglioni; Aafke Christine Kraan; Guido Baroni; Giuseppe Battistoni; Nicola Belcari; Andrea Berti; Pietro Carra; Piergiorgio Cerello; Mario Ciocca; Angelica De Gregorio; Micol De Simoni; Damiano Del Sarto; Marco Donetti; Yunsheng Dong; Alessia Embriaco; Maria Evelina Fantacci; Veronica Ferrero; Elisa Fiorina; Marta Fischetti; Gaia Franciosini; Giuseppe Giraudo; Francesco Laruina; Davide Maestri; Marco Magi; Giuseppe Magro; Etesam Malekzadeh; Michela Marafini; Ilaria Mattei; Enrico Mazzoni; Paolo Mereu; Alfredo Mirandola; Matteo Morrocchi; Silvia Muraro; Ester Orlandi; Vincenzo Patera; Francesco Pennazio; Marco Pullia; Alessandra Retico; Angelo Rivetti; Manuel Dionisio Da Rocha Rolo; Valeria Rosso; Alessio Sarti; Angelo Schiavi; Adalberto Sciubba; Giancarlo Sportelli; Sara Tampellini; Marco Toppi; Giacomo Traini; Antonio Trigilio; Serena Marta Valle; Francesca Valvo; Barbara Vischioni; Viviana Vitolo; Richard Wheadon; Maria Giuseppina Bisogni Journal: Front Oncol Date: 2022-09-26 Impact factor: 5.738